AUTHORS
Tarang Gaur, Simone Sidoli2, Christina Drenberg Guttke, PhD3, Shikhar Sharma, PhD4, Sovira Chaudhry5, Prathiba Jayaguru, PhD6, Kathryn Packman, PhD7, Swathi-Rao Narayanagari8, Varun Gupta9, Kritika Krishnamurthy, MD10, Marina Konopleva, MD, PhD11, Anna Skwarska, PhD12
AFFILIATIONS
1 Department of Oncology, Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, United States
2 Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, United States
3 Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania, United States
4 Department of Oncology, Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, United States
5 Department of Oncology, Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, United States
6 Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania, United States
7 Johnson & Johnson Innovative Medicine, Cambridge, Massachusetts, United States
8 Stem Cell Isolation and Xenotransplantation Facility, Albert Einstein College of Medicine, Bronx, New York, United States
9 Department of Oncology, Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, United States
10 Department of Anatomic and Clinical Pathology, Montefiore Medical Center, The University Hospital for Albert Einstein College of Medicine, Bronx, New York, United States
11 Department of Oncology, Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, United States
12 Department of Oncology, Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, United States
ABSTRACT
Introduction: AML harboring NPM1/FLT3-ITD mutations represents an aggressive molecular subset with inferior clinical outcomes despite the multi-agent therapies incorporating FLT3 inhibitors. Bleximenib (JNJ-75276617) is a highly potent, selective, oral Menin inhibitor that suppresses oncogenic transcription factors HOXA9 and MEIS1, relieving the myeloid differentiation block in KMT2A-rearranged and NPM1-mutant AML. We investigated co-targeting Menin-associated transcriptional program and oncogenic FLT3 signaling using bleximenib and FLT3 inhibitor gilteritinib.
Methods: Five NPM1/FLT3 co-mutated AML isolated from established PDX models were treated ex vivo in cytokine-enriched media with bleximenib, gilteritinib or combination for 10 days followed by assessment of cell counts, differentiation (anti-hCD11b, -CD15, -CD14 flow cytometry), and apoptosis (Annexin V/PI). From these, three PDX models were selected for evaluation of the in vivo efficacy in NSG mice. Following confirmation of engraftment, mice (n=5-10/ group) were randomized and treated with vehicle, bleximenib (30-50 mg/kg), gilteritinib (10 mg/kg), or the combination via oral gavage. AML tumor burden (hCD45+) and myeloid differentiation markers were assessed in peripheral blood by flow cytometry biweekly and analyzed by one-way ANOVA test. Survival was estimated using Kaplan-Meier curves with log-rank (Mantel-Cox) test. A separate cohort of 3-5 mice per group was evaluated for bone marrow and splenic tumor burden, spleen size and weight. Enriched hCD45+ cells were subjected to global proteomics and histone profiling. Single cell DNA sequencing combined with immunophenotyping (Tapestri Mission Bio) of purified leukemic cells from PDX#556 following treatment is ongoing.
Results: The ex vivo data from 5 PDX samples showed that treatments significantly decreased absolute viable cell counts (% viable cells normalized to vehicle: bleximenib 73.9 ±9.4%, gilteritinib 56.1±5.5%, combination 54.3±5.7%). Bleximenib and bleximenib/gilteritinib induced myeloid differentiation (%CD15, range: untreated 17-28%, bleximenib 58-70%, gilteritinib 21.7-50% and combination 59-75%, p<0.0001) with no significant change in CD11b or CD14 expression. Combined therapy induced a higher fraction of apoptotic cells (73%) in comparison to control (28.8%) or single agents (bleximenib, 58.8%; gilteritinib, 61.4%) (p= 0.0002, n=4).
In PDX#566 model (FLT3-ITD, NPM1, BCOR, DNMT3A, U2AF1), combined therapy significantly prolonged survival in mice relative to vehicle and monotherapy (median survival: 119 days for the combination versus 73 days for vehicle, 98 days for bleximenib, and 101 days for gilteritinib; p<0.0001). Similarly, PDX#374 (FLT3-ITD, NPM1, BCOR, DNMT3A) showed superior survival in comparison to vehicle and single agents (median survival: 153 days for the combination versus 87 days for vehicle, 125 days for bleximenib, and 95 days for gilteritinib; p<0.0001). Survival assessment in an additional independent PDX model #550 (FLT3-ITD, NPM1, IDH1, DNMT3A) is ongoing, with no mice remaining on study in the vehicle, gilteritinib, or bleximenib cohorts with median survival of 63 days in vehicle, 76 days in gilteritinib and 108 days in bleximenib, whereas all combination-treated animals remain alive at the time of analysis (days 118). A pharmacodynamic study in two PDX models showed that after 4 weeks of treatment combination therapy significantly reduced the splenic leukemic burden and increased the %CD15+ cells. No body weight changes were observed. The proteomic and histone profiling identified a combination-specific molecular signatures of SMAD4, MEAF6, MED13 involving transcriptional and chromatin-associated regulators not seen with either single agents or vehicle. Histone marker H3K56me1 was suppressed by single agents and further reduced in combination cohort consistent with block in proliferation (p= 0.012).
Conclusions: Dual targeting of Menin and FLT3-ITD by bleximenib and gilteritinib resulted in greater anti-leukemia efficacy associated with reduced proliferation, enhanced myeloid differentiation, and long-lasting disease control across independent FLT3-ITD/NPM1-mutant PDX models. These results provide support for clinical evaluation of combined Menin and FLT3 inhibition as a therapeutic strategy for high-risk NPM1/FLT3 co-mutated AML.
DISCLOSURES
Tarang Gaur: No relevant conflicts of interest to declare.